Naunyn Schmiedebergs Arch Pharmacol. 2026 May 1. doi: 10.1007/s00210-026-05404-8. Online ahead of print.
ABSTRACT
Astragaloside IV (AS-IV), a compound extracted from Radix Astragali, has been shown to have beneficial effects on cardiovascular disease. However, the role of AS-IV in cardiac toxicity caused by arsenic trioxide (ATO) is unknown. The current experiment aimed to explore the protective effects and molecular mechanisms of AS-IV against ATO-induced cardiac toxicity. Rats were administered AS-IV intragastrically (40, 80 mg/kg) concurrently with ATO (5 mg/kg) infused intraperitoneally over 7 days. Electrocardiography, cardiac weight index, and heart morphology changes were observed. Histopathological and cardiac function indices showed that ATO caused severe cardiac damage. It increased MDA levels while reducing SOD and GSH-Px, indicating oxidative damage. Inflammatory markers, including IL-1β and TNF-α, were markedly upregulated. Apoptosis, marked by upregulated Bax and decreased Bcl-2, was enhanced. However, AS-IV treatment significantly suppressed these changes. Moreover, AS-IV treatment resulted in a significant decrease in the protein expression levels of p38MAPK and NF-κB. The findings revealed that AS-IV may inhibit the inflammation, apoptosis, and oxidative stress to exert protective effects on ATO-induced cardiac toxicity in rats through inhibiting the p38MAPK/NF-κB signaling pathway.
PMID:42065762 | DOI:10.1007/s00210-026-05404-8